![]() ![]() BRILINTA is contraindicated in patients with a history of intracranial hemorrhage or active pathological bleeding such as peptic ulcer or intracranial hemorrhage.Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided.Stopping BRILINTA increases the risk of subsequent cardiovascular eventsī. If possible, manage bleeding without discontinuing BRILINTA.Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery.Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage.BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS ![]() IMPORTANT SAFETY INFORMATION FOR BRILINTA (ticagrelor) 60-MG AND 90-MG TABLETS In the second half of 2016, data are expected from the ongoing EUCLID trial in PAD, which is the fourth trial to read-out from the PARTHENON program, assessing the potential of BRILINTA in additional high-risk patient populations.īRILINTA is not approved for the prevention of cardiovascular events in patients with PAD, stroke or diabetes who have not experienced a prior MI. The data will be presented on April 3 and 4 respectively. The sub-analyses include prior MI patients with either peripheral artery disease (PAD) or diabetes. Data will be presented on two new sub-analyses from the PEGASUS trial. This update comes ahead of American College of Cardiology's 65th Annual Scientific Sessions. BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. For at least the first 12 months following ACS, it has been proven superior to clopidogrel. In the US, BRILINTA is indicated to reduce the rate of CV death, MI, and stroke in patients with ACS or a history of MI. ![]() BRILINTA is the only P2Y12 inhibitor that has been approved by the FDA in the past 10 years, for long-term use in patients with a history of MI. The US Food and Drug Administration approved BRILINTA at a 60mg dose for patients with a history of heart attack in September 2015. This update reflects the clinical confidence of BRILINTA as a treatment option for heart attack patients in the acute setting and in the longer-term.” Full details of the updated guideline are available on the ACC website.Įlisabeth Bjork, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca said: “We are pleased that the ACC/AHA have further recognized the role of BRILINTA across a broad spectrum of ACS. ![]() The guideline supports continuation of P2Y12 therapy beyond 12 months in prior MI patients who are not at high bleeding risk (Class IIb LOE: A). The update is also the first US guideline to provide the medical community with insights drawn from the PEGASUS-TIMI 54 trial. This update is the first time the ACC/AHA has recommended BRILINTA over clopidogrel for patients who have experienced a ST-elevation myocardial infarction (STEMI). BRILINTA (ticagrelor) is now preferred over clopidogrel for the management of patients with acute coronary syndrome (ACS) who have received a coronary stent and in non-ST Elevation acute coronary syndrome (NSTE-ACS) patients treated with medical therapy alone (Class IIa LOE: B-R). First major US guideline to include expanded indication for BRILINTA in patients with a heart attack beyond one yearĪstraZeneca today confirmed that the American College of Cardiology (ACC) and American Heart Association (AHA) have released a treatment guideline on the duration of dual antiplatelet therapy (DAPT). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |